CA3061301C - Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose - Google Patents

Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose Download PDF

Info

Publication number
CA3061301C
CA3061301C CA3061301A CA3061301A CA3061301C CA 3061301 C CA3061301 C CA 3061301C CA 3061301 A CA3061301 A CA 3061301A CA 3061301 A CA3061301 A CA 3061301A CA 3061301 C CA3061301 C CA 3061301C
Authority
CA
Canada
Prior art keywords
compound
formula
acid
hydrate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3061301A
Other languages
English (en)
Other versions
CA3061301A1 (fr
Inventor
Do Kyu Pyun
Kyoung Jin Oo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JW Pharmaceutical Corp
Original Assignee
JW Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JW Pharmaceutical Corp filed Critical JW Pharmaceutical Corp
Priority to CA3150710A priority Critical patent/CA3150710C/fr
Publication of CA3061301A1 publication Critical patent/CA3061301A1/fr
Application granted granted Critical
Publication of CA3061301C publication Critical patent/CA3061301C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/10—Halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une méthode de préparation d'un composé dérivé hétérocyclique de formule chimique I ci-dessous, un nouveau composé intermédiaire utilisé dans la méthode de préparation, une composition pour le traitement ou la prévention de l'hyperuricémie, de la goutte, de la néphrite, de l'insuffisance rénale chronique, de la néphrolithiase, de l'urémie, de l'urolithiase ou d'une maladie liée à l'acide urique, la composition contenant le composé de formule chimique I en une dose de plus de 2 mg et plus petite ou égale à 10 mg par voie buccale une fois par jour et un chlorhydrate-1.5-hydrate du nouveau composé de formule chimique I, la formule I étant :
CA3061301A 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose Active CA3061301C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3150710A CA3150710C (fr) 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170064914 2017-05-25
KR10-2017-0064914 2017-05-25
PCT/KR2018/005932 WO2018217050A1 (fr) 2017-05-25 2018-05-24 Procédé de préparation d'un composé dérivé hétérocyclique, composition le contenant, et hydrate dudit composé

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3150710A Division CA3150710C (fr) 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose

Publications (2)

Publication Number Publication Date
CA3061301A1 CA3061301A1 (fr) 2019-10-23
CA3061301C true CA3061301C (fr) 2022-05-31

Family

ID=64396846

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3150710A Active CA3150710C (fr) 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose
CA3061301A Active CA3061301C (fr) 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3150710A Active CA3150710C (fr) 2017-05-25 2018-05-24 Procede de preparation d'un compose derive heterocyclique, composition le contenant, et hydrate dudit compose

Country Status (25)

Country Link
US (6) US20200207784A1 (fr)
EP (3) EP3909956B1 (fr)
JP (4) JP2020521007A (fr)
KR (1) KR102307504B1 (fr)
CN (3) CN114085235B (fr)
AU (1) AU2018273020B2 (fr)
CA (2) CA3150710C (fr)
DK (1) DK3909956T3 (fr)
EA (1) EA201992801A1 (fr)
ES (2) ES2907590T3 (fr)
FI (1) FI3909956T3 (fr)
HR (1) HRP20250183T1 (fr)
HU (1) HUE070148T2 (fr)
IL (2) IL294127B2 (fr)
LT (1) LT3909956T (fr)
MX (2) MX393863B (fr)
MY (1) MY201054A (fr)
NZ (2) NZ758513A (fr)
PH (1) PH12019502418B1 (fr)
PL (2) PL3909956T3 (fr)
PT (1) PT3909956T (fr)
SI (1) SI3909956T1 (fr)
TW (2) TWI837089B (fr)
WO (1) WO2018217050A1 (fr)
ZA (1) ZA201908433B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021079225A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021087836A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP7556432B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556433B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556434B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197291A (ja) * 1984-10-17 1986-05-15 Yamanouchi Pharmaceut Co Ltd ７−〔α−（２−アミノ−４−チアゾリル）−α−（低級アルコキシイミノ）アセトアミド〕−３−〔６−（２Ｈ−ピリド〔４，３−ｂ〕−１，４−オキサジニオ）メチル〕−Δ３−セフエム−４−カルボキシレ−トおよびその製造法
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP3988832B2 (ja) * 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
JP4646068B2 (ja) * 2005-09-30 2011-03-09 国立大学法人東京工業大学 ポジ型感光性樹脂組成物、その製造方法、及びレリーフパターンの形成方法
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation
JP5314123B2 (ja) * 2008-03-31 2013-10-16 シー アンド シー リサーチ ラボラトリーズ 複素環誘導体
EP2281128B1 (fr) * 2008-04-28 2019-08-28 Robert Bosch GmbH Composant annulaire pour courroie d'entraînement, procédé de fabrication et matériau de base d'acier à trempe secondaire martensitique pour ce composant

Also Published As

Publication number Publication date
CN119143779A (zh) 2024-12-17
EP3909955A1 (fr) 2021-11-17
MX2019013937A (es) 2020-02-07
CN114085235A (zh) 2022-02-25
EP3632917A4 (fr) 2020-07-01
CN110691783A (zh) 2020-01-14
AU2018273020B2 (en) 2020-10-15
US20240083911A1 (en) 2024-03-14
HRP20250183T1 (hr) 2025-04-11
US12497410B2 (en) 2025-12-16
IL270789B1 (en) 2023-05-01
US20220363691A1 (en) 2022-11-17
EP3909956B1 (fr) 2024-12-04
TW201900652A (zh) 2019-01-01
JP2022126729A (ja) 2022-08-30
EA201992801A1 (ru) 2020-03-19
KR102307504B1 (ko) 2021-09-30
NZ758513A (en) 2022-02-25
ZA201908433B (en) 2021-04-28
EP3632917A1 (fr) 2020-04-08
CA3150710C (fr) 2023-10-10
JP7796815B2 (ja) 2026-01-09
CN114085235B (zh) 2024-08-13
FI3909956T3 (fi) 2025-02-21
MX393863B (es) 2025-03-21
US12030895B2 (en) 2024-07-09
KR20190132693A (ko) 2019-11-28
JP2024129161A (ja) 2024-09-26
EP3909956A1 (fr) 2021-11-17
TWI837089B (zh) 2024-04-01
DK3909956T3 (da) 2025-03-03
US20260070923A1 (en) 2026-03-12
NZ780383A (en) 2025-12-19
HUE070148T2 (hu) 2025-05-28
EP3632917B1 (fr) 2021-11-17
US20240067659A1 (en) 2024-02-29
SI3909956T1 (sl) 2025-04-30
JP2020521007A (ja) 2020-07-16
TW202411234A (zh) 2024-03-16
IL270789B2 (en) 2023-09-01
ES3011357T3 (en) 2025-04-07
IL294127B2 (en) 2024-07-01
JP2024129160A (ja) 2024-09-26
PL3632917T3 (pl) 2022-04-11
JP7557500B2 (ja) 2024-09-27
US20220340594A1 (en) 2022-10-27
PL3909956T3 (pl) 2025-04-07
WO2018217050A1 (fr) 2018-11-29
US20200207784A1 (en) 2020-07-02
PH12019502418B1 (en) 2023-12-06
ES2907590T3 (es) 2022-04-25
US11866448B2 (en) 2024-01-09
IL270789A (en) 2020-01-30
AU2018273020A1 (en) 2019-11-14
MX2022005722A (es) 2022-06-09
PT3909956T (pt) 2025-02-21
CA3061301A1 (fr) 2019-10-23
MY201054A (en) 2024-01-31
PH12019502418A1 (en) 2020-07-06
BR112019024253A2 (pt) 2020-06-02
IL294127B1 (en) 2024-03-01
US12103938B2 (en) 2024-10-01
LT3909956T (lt) 2025-03-10
IL294127A (en) 2022-08-01
CA3150710A1 (fr) 2019-10-23

Similar Documents

Publication Publication Date Title
US12103938B2 (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
HK40114586A (zh) 杂环衍生物化合物的制备方法、包含所述化合物的组合物及所述化合物的水合物
HK40065441B (zh) 杂环衍生物化合物的制备方法、包含所述化合物的组合物及所述化合物的水合物
HK40065441A (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
EA047565B1 (ru) Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения
BR112019024253B1 (pt) Processos para preparar um composto, ou um sal farmaceuticamente aceitável do mesmo ou um hidrato do mesmo, e para preparar 1,5 hidrato de cloridrato do composto, composto, composição farmacêutica, e, 1,5 hidrato (sesqui-hidrato) de cloridrato do composto
HK40018060A (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
EA042271B1 (ru) Способ лечения с помощью соединения гетероциклического производного
WO2024260312A1 (fr) Formes cristallines de sel de sodium d'un dérivé de carbamoylpyridone polycyclique, leur procédé de préparation et leur utilisation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250320